In naming its most innovative companies, Fast Company is "honoring leading enterprises and rising newcomers that exemplify the best in nimble business and impactful innovation." Winners this time include Amazon, Apple, Facebook, Netflix.
To produce the 2017 list, Fast Company reporters surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture. The coverage also highlights Top 10 lists in 36 sectors and geographies, from artificial intelligence to health to travel.
A big reason the magazine recognized Abbott this year is for our AbsorbTM stent, the world's first fully dissolving heart stent. Approved by the Food and Drug Administration in the U.S., Absorb is implanted in patients around the globe and available in more than 100 countries.
This section of our guiding anthem is particularly appropriate today: "Abbott has long been in the business of life. Creating more possibilities for more people through the power of health. But this business is not about reflecting on past achievements. It is about relentlessly pursuing new ones."
Thanks, Fast Company.
MORE OF ABBOTT'S LATEST BREAKTHROUGHS
*FREESTYLE LIBRE & FREESTYLE LIBRE PRO: Abbott’s new sensing technology, FreeStyle LibreTM and FreeStyle LibreTM ProTM systems are in many ways the devices people with diabetes have been waiting for. Both devices are factory-calibrated and provide users and the healthcare professionals with data that enable better diabetes management. FreeStyle Libre system is currently available across 32 countries globally and is currently under review in the U.S. (pending FDA approval and not available for sale in the U.S.); FreeStyle Libre Pro system is available in India, South Africa and the U.S. TO LEARN MORE ABOUT FREESTYLE LIBRE™ PRO™, PLEASE CLICK HERE.
ALINITY: Diagnostic testing influences as much as 70 percent of health care decisions. Global testing volumes are rising. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs. Our solution? AlinityTM, our harmonized family of next-generation systems across lab disciplines. Each AlinityTM platform includes a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment. TO LEARN MORE ABOUT ALINITYTM, PLEASE CLICK HERE.
ENSITE PRECISION: In arrhythmia management, advanced cardiac mapping is complex. For doctors to make sound decisions, they need precise information and they need it quickly. Our EnSite PrecisionTM cardiac mapping system offers next-generation technology that allows for a high level of automation, flexibility and precision to help doctors more effectively diagnose a wide range of arrhythmias (abnormal heart rhythms). TO LEARN MORE ABOUT ENSITE PRECISIONTM, PLEASE CLICK HERE.
REALTIME ZIKA TEST: Our test to identify Zika virus ribonucleic acid (RNA) in plasma, serum and urine is now also authorized by the FDA to detect the virus in whole blood, a first from a commercial manufacturer in the U.S. Zika can be detected in whole blood for a longer period of time (up to two months) and at higher levels versus testing with serum and urine sample types. Abbott’s test could provide a more accurate diagnosis, helping people get treated and get back to better health faster. TO LEARN MORE ABOUT OUR REALTIME ZIKA TEST, PLEASE CLICK HERE.
MITRACLIP: When the mitral valve — located between your heart's two left chambers — fails to close completely, blood leaks backward inside your heart, causing a condition called mitral regurgitation, placing an extra burden on your heart and lungs. MitraClip® can help. Clinical data from MitraClip patients show an immediate reduction of mitral regurgitation and a low average hospital length of stay of 2.9 days. Many patients report they experience significant improvement in symptoms and quality of life soon after the procedure. TO LEARN MORE ABOUT MITRACLIP, PLEASE CLICK HERE.
Infographic: Innovation by the Numbers
*FreeStyle Libre Pro Indications and Important Safety Information
The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns and glucose level excursions above or below the desired range, facilitating therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for use by health care professionals and requires a prescription.
IMPORTANT: The device may inaccurately indicate hypoglycemia. The results of the clinical study conducted for this device showed that 40% of the time when the device indicated that user sensor glucose values were at or below 60 mg/dL, user glucose values were actually in the range of 81-160 mg/dL. Therefore, interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should only be based on the trends and patterns analyzed through time using the reports available per the intended use.
CONTRAINDICATIONS: Remove the Sensor before MRI, CT scan, X-ray, or diathermy treatment.
WARNINGS/LIMITATIONS: The FreeStyle Libre Pro System does not provide real-time results and patients should adhere to their blood glucose monitoring routine while using the system. If a sensor breaks, contact physician and call Customer Service. Patients with high levels of ascorbic acid (Vitamin C) or salicylic acid (used in Aspirin) or severe dehydration or excessive water loss or medications containing acetaminophen (Tylenol) may experience inaccurate results with this system.
The FreeStyle Libre Pro System is not approved for pregnant women, persons on dialysis, or recommended for critically ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken.
Review all product information before use or contact Abbott toll-free (855-632-5297) or visit www.FreeStyleLibrePro.us for detailed indications for use and safety information.
AP2943714-WBU Rev. A
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.